Findings
Significant changes to device design, basic principles of operation, or clinical protocols require prior FDA approval through an IDE supplement.
Developmental changes made in response to information gathered during a clinical investigation and minor protocol modifications may be implemented with a 5-day notice if they meet specified criteria.
Changes that do not affect the scientific soundness of the investigational plan, risk-benefit profile, or participant rights and safety can be reported in an IDE annual progress report.
Sponsors are responsible for conducting risk analyses and using credible information, such as design controls or peer-reviewed literature, to justify changes.
The FDA reserves the right to question the appropriateness of changes implemented without prior approval.

Recommendations
Conduct a risk analysis for any device or protocol change and ensure no new risks are introduced.
Use credible information, such as design control data, preclinical testing, or published literature, to assess the impact of proposed changes.
Submit IDE supplements for significant design or protocol changes that affect the validity of study data, participant safety, or investigational plan soundness.
Use the 5-day notice process for developmental changes that improve safety or effectiveness but do not represent significant design changes.
Report minor investigational plan changes, such as clarifying instructions or updating IRB information, in the IDE annual progress report.

Regulatory Considerations
IDE Supplements: Required for significant changes to device design, manufacturing processes, or protocols that may impact study data validity, risk-benefit analysis, or participant safety.
5-Day Notices: Applicable for developmental changes and protocol modifications that do not introduce new risks or affect study soundness.
Annual Progress Reports: Used for minor changes, including clarifications to instructions for use or informed consent materials, provided they do not affect participant safety or study data integrity.
FDA reserves the right to reclassify changes implemented under a 5-day notice or annual report if they determine the changes required prior approval.